SGLT2 inhibitors: the latest "new kids on the block"!

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Diabetes, obesity & metabolism · 2017
   Trial
2. SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century?Nutrients · 2023
   Review
3. The Anti-Inflammatory Effect of Novel Antidiabetic Agents.Life (Basel, Switzerland) · 2022
   Review
4. Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report.Annals of coloproctology · 2021
   Article
5. Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.Diabetes, obesity & metabolism · 2020
   Article
6. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.The American journal of case reports · 2020
   Article
7. Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.Cureus · 2019
   Article
8. Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients.Current cardiology reports · 2018
   Review
9. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Heart failure reviews · 2018
   Review
10. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series.Endocrine · 2018
    Article
11. Canagliflozin: A Review in Type 2 Diabetes.Drugs · 2017
    Review
12. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.Diabetology & metabolic syndrome · 2017
    Article
13. Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting: Part 2: Pharmacology and Guidelines for Perioperative Management.Anesthesia progress · 2017
    Review
14. Building Momentum: Taking on the Real “Issues” of Diabetes Care!Diabetes care · 2016
    Article
15. Management of pancreatogenic diabetes: challenges and solutions.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016
    Review
16. Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!Diabetes care · 2015
    Article
17. Type 1 diabetes at a crossroads!Diabetes care · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as